01. Actively Recruiting Clinical Trials
Mesothelioma Clinical Trials Currently Accepting Patients
Mesothelioma patients may consider participating in a clinical trial. Clinical trials are medical studies involving people. There are dozens of active clinical trials recruiting mesothelioma patients who meet the eligibility requirements.
Doctors use mesothelioma clinical studies to evaluate the safety and efficacy of new treatments. If treatments perform well in clinical trials, they can go on to become approved by the U.S. Food and Drug Administration (FDA).
One example of this is the immunotherapy combination of Opdivo® and Yervoy®. Together, these drugs proved successful in clinical trials. Researchers found the combination extended patient survival. Based upon that data, the FDA approved Opdivo® and Yervoy® for the treatment of inoperable pleural mesothelioma.
These important medical studies follow a defined process. Each mesothelioma clinical trial starts with an idea, often in a research laboratory. Treatments that perform well in the lab and in animals can move on to clinical trials testing. This is the point at which researchers allow people to volunteer to help evaluate the new treatment(s).
Mesothelioma patients with limited treatment options may be able to access new treatments through clinical trials. In fact, the American Society of Clinical Oncology (ASCO) recommends clinical trial enrollment for the following pleural mesothelioma patients:
- Patients qualifying for a second round of systemic chemotherapy (second-line) after failure of primary chemotherapy treatment
- Patients with mesothelioma tumors or cells in nearby lymph nodes
- Patients qualifying for pre-surgical or post-surgical radiation therapy
Like all medical treatments, clinical trial participation comes with certain risks. Patients should discuss the potential benefits and risks of enrolling in a clinical trial with their oncologists.
Additional information on clinical trial safety, process, costs and enrollment can be found on our Clinical Trials Overview page.
02. List of Open Clinical Trials
List of Clinical Trials Recruiting Mesothelioma Patients
Provided below is a list of mesothelioma trials that are currently accepting new patients.
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
Conditions: Carcinoma, Neoplasms, Small Cell Lung Carcinoma, Endometrial Neoplasms, Thyroid Neoplasms, Mesothelioma, Neuroendocrine Tumors, Cholangiocarcinoma, Colorectal Neoplasms, Salivary Gland Neoplasms, Carcinoid Tumor, Anus Neoplasms, Bile Duct Neoplasms, Vulvar Neoplasms, Thyroid Diseases
Last Updated: February 5, 2024
Status: Recruiting
Locations: Los Angeles, CA. Orlando, FL. Boston, MA. New Brunswick, NJ.
Integrated Cancer Repository for Cancer Research (iCaRe2)
Conditions: Neoplasms, Multiple Myeloma, Pancreatic Neoplasms, Esophageal Neoplasms, Endometrial Neoplasms, Thyroid Neoplasms, Mesothelioma, Neuroendocrine Tumors, Salivary Gland Neoplasms, Anus Neoplasms, Gallbladder Neoplasms, Bile Duct Neoplasms, Oropharyngeal Neoplasms, Nasopharyngeal Neoplasms, Nasopharyngeal Carcinoma, Urethral Neoplasms, Vaginal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Adenomatous Polyposis Coli, Colorectal Neoplasms, Hereditary Nonpolyposis, Testicular Neoplasms, Intestinal Neoplasms, Hypopharyngeal Neoplasms, Penile Neoplasms, Ureteral Neoplasms, Neoplasms, Plasma Cell, Peritoneal Neoplasms, Paranasal Sinus Neoplasms, Neoplasms, Unknown Primary, Duodenal Neoplasms, Lip Neoplasms, Thymus Neoplasms, Paraproteinemias
Last Updated: August 9, 2023
Status: Recruiting
Locations: Colorado Springs, CO. Denver, CO. Durango, CO. Lakewood, CO. Littleton, CO. Longmont, CO. Louisville, CO. Parker, CO. Pueblo, CO. Westminster, CO. Daytona Beach, FL. DeLand, FL. Orange City, FL. Palm Coast, FL. Aurora, IL. Moline, IL. Yorkville, IL. Fort Wayne, IN. Indianapolis, IN. Indianapolis, IN. Indianapolis, IN. Kokomo, IN. Council Bluffs, IA. Davenport, IA. Spencer, IA. Waterloo, IA. Overland Park, KS. New Orleans, LA. Portland, ME. Randallstown, MD. Westminster, MD. Holyoke, MA. Ann Arbor, MI. Aitkin, MN. Brainerd, MN. Duluth, MN. Duluth, MN. Fergus Falls, MN. Marshall, MN. Joplin, MO. Kansas City, MO. Kansas City, MO. Kansas City, MO. Liberty, MO. Saint Joseph, MO. Kalispell, MT. Missoula, MT. Hastings, NE. Norfolk, NE. North Platte, NE. O'Neill, NE. Omaha, NE. Omaha, NE. Omaha, NE. Scottsbluff, NE. Glens Falls, NY. Utica, NY. Fayetteville, NC. Fargo, ND. Minot, ND. Pittsburgh, PA. Aberdeen, SD. Mitchell, SD. Sioux Falls, SD. Sioux Falls, SD. Yankton, SD. Yankton, SD. Yankton, SD. Rutland, VT. Fredericksburg, VA. Appleton, WI. Brookfield, WI. Franklin, WI. Mequon, WI. Milwaukee, WI. Oshkosh, WI. Racine, WI. Wauwatosa, WI.
Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma
Conditions: Mesothelioma, Mesothelioma, Malignant, Lung Neoplasms
Last Updated: March 28, 2023
Status: Recruiting
Locations: Coral Gables, FL. Deerfield Beach, FL. Miami, FL. Tampa, FL. Tampa, FL. Tampa, FL. Chicago, IL. Boston, MA. Rochester, MN. Basking Ridge, NJ. Middletown, NJ. Montvale, NJ. Commack, NY. Harrison, NY. New York, NY. New York, NY. Uniondale, NY. Cleveland, OH. Columbus, OH. Houston, TX. Seattle, WA.
Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors
Conditions: Carcinoma, Melanoma, Mesothelioma, Oropharynx Cancer, Renal Cell Carcinoma, Solid Tumor
Last Updated: March 10, 2023
Status: Recruiting
Locations: Phoenix, AZ. Jacksonville, FL. Miami, FL. Kansas City, KS. Boston, MA. Rochester, MN. Billings, MT. Houston, TX.
Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)
Conditions: Mesothelioma, Mesothelioma, Malignant
Last Updated: November 1, 2022
Status: Recruiting
Locations: Philadelphia, PA.
Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies
Conditions: Mesothelioma, Mesothelioma, Malignant, Gastrointestinal Neoplasms, Carcinoma, Peritoneal Neoplasms, Appendiceal Neoplasms
Last Updated: October 31, 2022
Status: Recruiting
Locations: Bethesda, Maryland.
Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining
Conditions: Esophageal Neoplasms, Mesothelioma, Mesothelioma, Malignant, Neoplasms
Last Updated: October 27, 2022
Status: Recruiting
Locations: Bethesda, Maryland.
Rapid Autopsy and Procurement of Cancer Tissue
Conditions: Mesothelioma, Urogenital Neoplasms
Last Updated: October 26, 2022
Status: Recruiting
Locations: Bethesda, Maryland.
Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma
Conditions: Mesothelioma, Mesothelioma, Malignant, Lung Neoplasms
Last Updated: October 25, 2022
Status: Recruiting
Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for, Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas
Conditions: Carcinoma, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Mesothelioma, Malignant, Esophageal Neoplasms
Last Updated: October 25, 2022
Status: Recruiting
Locations: Bethesda, MD.
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
Conditions: Carcinoma, Merkel Cell, Carcinoma, Neoplasms, Carcinoma, Squamous Cell, Small Cell Lung Carcinoma, Mesothelioma, Nasopharyngeal Carcinoma, Esophageal Squamous Cell Carcinoma
Last Updated: October 24, 2022
Status: Recruiting
Locations: Boston, MA. Detroit, MI. Pittsburgh, PA. Houston, TX. Seattle, WA.
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
Conditions: Carcinoma, Merkel Cell, Carcinoma, Neoplasms, Carcinoma, Squamous Cell, Carcinoma, Renal Cell, Small Cell Lung Carcinoma, Mesothelioma, Nasopharyngeal Carcinoma, Carcinoma, Basal Cell, Esophageal Squamous Cell Carcinoma, Endometrial Neoplasms
Last Updated: October 21, 2022
Status: Recruiting
Locations: Hackensack, NJ. Greenville, SC. Nashville, TN.
The Registry of Oncology Outcomes Associated With Testing and Treatment
Conditions: Sarcoma, Kaposi, Carcinoma, Neoplasms, Leukemia, Leukemia, Myeloid, Multiple Myeloma, Pancreatic Neoplasms, Sarcoma, Glioblastoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Colonic Neoplasms, Esophageal Neoplasms, Liver Neoplasms, Astrocytoma, Mesothelioma, Neuroendocrine Tumors, Fallopian Tube Neoplasms, Nasopharyngeal Carcinoma, Cholangiocarcinoma, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Osteosarcoma, Waldenstrom Macroglobulinemia, Salivary Gland Neoplasms, Carcinoid Tumor, Anus Neoplasms, Bile Duct Neoplasms, Head and Neck Neoplasms, Vulvar Neoplasms, Liposarcoma, Pheochromocytoma, Vaginal Neoplasms, Stomach Neoplasms, Chondrosarcoma, Sarcoma, Synovial, Uterine Neoplasms, Testicular Neoplasms, Tongue Neoplasms, Carcinoma, Small Cell, Small Cell Lung Carcinoma, Trophoblastic Neoplasms, Gestational Trophoblastic Disease, Penile Neoplasms, Ureteral Neoplasms, Endocrine Gland Neoplasms, Multiple Endocrine Neoplasia, Laryngeal Neoplasms, Bone Neoplasms, Adrenal Gland Neoplasms, Parathyroid Neoplasms, Neoplasms, Unknown Primary, Appendiceal Neoplasms, Pharyngeal Neoplasms, Thymus Neoplasms, Brain Stem Neoplasms, Carcinoma, Adenoid Cystic
Last Updated: October 19, 2022
Status: Recruiting
Locations: Idaho Falls, ID.
A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors
Conditions: Mesothelioma, Mesothelioma, Malignant
Last Updated: October 18, 2022
Status: Recruiting
Locations: Chicago, Illinois. Boston, Massachusetts. Houston, Texas.
Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs
Conditions: Carcinoma, Lung Neoplasms, Mesothelioma, Cholangiocarcinoma, Pleural Effusion
Last Updated: October 17, 2022
Status: Recruiting
Locations: Columbus , GA.
Mass Response of Malignant Fluid Cells as a Biomarker for Rapid Therapy Guidance
Conditions: Carcinoma, Melanoma, Mesothelioma
Last Updated: October 17, 2022
Status: Recruiting
Locations: Oakland, California.
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Conditions: Mesothelioma
Last Updated: October 13, 2022
Status: Recruiting
Locations: Los Angeles, California. San Diego, California. Santa Monica, California. Tampa, Florida. Covington, Louisiana. New York, New York. Durham, North Carolina. Cincinnati, Ohio. Cleveland, Ohio. Columbus, Ohio. Pittsburgh, Pennsylvania. Nashville, Tennessee. Houston, Texas. Fredericksburg, Virginia. Lynchburg, Virginia. Madison, Wisconsin.
A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants
Conditions: Mesothelioma, Mesothelioma, Malignant
Last Updated: October 10, 2022
Status: Recruiting
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
Conditions: Pancreatic Cancer, Cholangiocarcinoma, Mesothelioma, Non Small Cell Lung Cancer, Cervical Cancer, Gastric Cancer, Breast Cancer, Endocervical Cancer, Squamous Cell Carcinoma of Head and Neck, Colorectal Cancer, Melanoma, Prostate Cancer, Ovarian Cancer
Last Updated: October 10, 2022
Status: Recruiting
Locations: New Haven, Connecticut. Detroit, Michigan. New York, New York. Houston, Texas.
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
Conditions: Mesothelioma
Last Updated: October 10, 2022
Status: Recruiting
Locations: Gilbert, Arizona. Los Angeles, California. Sarasota, Florida. Grand Rapids, Michigan. Austin, Texas. Houston, Texas.
A Study of HFB200301 in Adult Patients With Advanced Solid Tumors
Conditions: Mesothelioma, Gastric Cancer, Melanoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Sarcoma, Head and Neck Squamous Cell Carcinoma
Last Updated: October 7, 2022
Status: Recruiting
Locations: Scottsdale, Arizona. Los Angeles, California. Jacksonville, Florida. Rochester, Minnesota. Saint Louis, Missouri. Houston, Texas. Fairfax, Virginia.
A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas
Conditions: Lymphoma, Neoplasms, Lymphoma, Large B-Cell, Diffuse, Mesothelioma, Mesothelioma, Malignant, Prostatic Neoplasms, Lymphoma, T-Cell, Prostatic Neoplasms, Castration-Resistant
Last Updated: October 6, 2022
Status: Recruiting
Locations: Atlanta, GA. Chicago, IL. Baltimore, MD. Boston, MA. Boston, MA. Ann Arbor, MI. Grand Rapids, MI. Hackensack, NJ. Bronx, NY. New York, NY. Cincinnati, OH. San Antonio, TX. Charlottesville, VA. Seattle, WA.
Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma
Conditions: Mesothelioma, Mesothelioma, Malignant
Last Updated: October 5, 2022
Status: Recruiting
Locations: Bethesda, Maryland.
Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome
Conditions: Mesothelioma, Mesothelioma, Malignant, Syndrome, Disease Susceptibility
Last Updated: October 5, 2022
Status: Recruiting
Locations: Bethesda, MD.
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
Conditions: Neoplasms, Mesothelioma, Mesothelioma, Malignant, Pancreatic Neoplasms, Stomach Neoplasms, Thymoma, Biliary Tract Neoplasms
Last Updated: October 5, 2022
Status: Recruiting
Locations: Bethesda, Maryland.
Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Conditions: Any Solid Tumors, Mesothelioma, Head and Neck Squamous Cell Carcinoma, Ovarian Cancer, Hepatocellular Carcinoma, Squamous Cell Carcinoma of Lung, Esophageal Cancer, Adenoid Cystic Carcinoma, Prostate Cancer, Cervical Cancer, Melanoma
Last Updated: September 30, 2022
Status: Recruiting
Locations: Duarte, California. New York, New York. Houston, Texas. Milwaukee, Wisconsin. Canton, Ohio.
Chemotherapy Followed by Surgery and Neoadjuvant Hemothoracic Intensity Modified Radiation Therapy (IMRT) for Patients With Malignant Pleural Mesothelioma
Conditions: Mesothelioma, Mesothelioma, Malignant, Neoplasms, Fibrous Tissue, Solitary Fibrous Tumors, Pleural Neoplasms, Solitary Fibrous Tumor, Pleural, Hemangiopericytoma
Last Updated: September 28, 2022
Status: Recruiting
Locations: Rochester, MN.
Staging Procedures to Diagnose Malignant Pleural Mesothelioma
Conditions: Mesothelioma, Mesothelioma, Malignant, Neoplasms, Fibrous Tissue, Solitary Fibrous Tumors, Pleural Neoplasms, Solitary Fibrous Tumor, Pleural
Last Updated: September 28, 2022
Status: Recruiting
Locations: Rochester, MN.
Stereotactic Magnetic Resonance Guided Radiation Therapy
Conditions: Prostatic Neoplasms, Neoplasm Metastasis, Neoplasms, Second Primary, Brain Neoplasms, Mesothelioma, Pancreatic Neoplasms, Kidney Neoplasms, Carcinoma, Renal Cell
Last Updated: September 27, 2022
Status: Recruiting
Locations: Boston, MA. Boston, MA.
Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors
Conditions: Neoplasms, Melanoma, Mesothelioma, Mesothelioma, Malignant, Skin Neoplasms, Lung Neoplasms, Bone Neoplasms, Genital Neoplasms, Female, Soft Tissue Neoplasms, Pharyngeal Neoplasms, Endocrine Gland Neoplasms, Mouth Neoplasms, Urologic Neoplasms, Thyroid Neoplasms, Genital Neoplasms, Male, Sarcoma, Thyroid Diseases, Recurrence
Last Updated: September 26, 2022
Status: Recruiting
Locations: Houston, TX.
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
Conditions: Neoplasms, Adenocarcinoma, Mesothelioma, Cystadenocarcinoma, Serous
Last Updated: September 22, 2022
Status: Recruiting
Locations: Bethesda, Maryland. Nashville, Tennessee.
Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Conditions: Carcinoma, Glioblastoma, Mesothelioma, Cholangiocarcinoma, Squamous Cell Carcinoma of Head and Neck
Last Updated: September 15, 2022
Status: Recruiting
Locations: Los Angeles, California. Newport Beach, California. Santa Monica, California. Sarasota, Florida. Baltimore, Maryland. Boston, Massachusetts. Grand Rapids, Michigan. Omaha, Nebraska. Greenville, South Carolina. Houston, Texas. San Antonio, Texas.
A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers
Conditions: Mesothelioma
Last Updated: September 15, 2022
Status: Recruiting
Locations: Houston, Texas.
Dose Individualization of Pemetrexed - IMPROVE-I
Conditions: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Mesothelioma, Malignant
Last Updated: September 10, 2022
Status: Recruiting
Surgery for Mesothelioma After Radiation Therapy "SMART" for Resectable Malignant Pleural Mesothelioma
Conditions: Mesothelioma, Mesothelioma, Malignant, Neoplasms, Fibrous Tissue, Solitary Fibrous Tumors, Pleural Neoplasms, Solitary Fibrous Tumor, Pleural
Last Updated: September 8, 2022
Status: Recruiting
Locations: Rochester, MN.
Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer
Conditions: Carcinoma, Melanoma, Mesothelioma
Last Updated: September 1, 2022
Status: Recruiting
Locations: Boston, Massachusetts.
A Study of Pembrolizumab and Radiation Therapy in People With Mesothelioma
Conditions: Mesothelioma, Mesothelioma, Malignant
Last Updated: August 26, 2022
Status: Recruiting
Locations: Basking Ridge, New Jersey. Middletown, New Jersey. Montvale, New Jersey. Commack, New York. Harrison, New York. New York, New York. Rockville Centre, New York.
Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma
Conditions: Mesothelioma
Last Updated: August 25, 2022
Status: Recruiting
Locations: Phoenix, AZ. Chicago, IL. Danville, IL. Effingham, IL. Matoon, IL. Urbana, IL. Lexington, KY. Boston, MA. Bemidji, MN. Edina, MN. Minneapolis, MN. Rochester, MN. Bismarck, ND. Fargo, ND. Columbus, OH. Oklahoma City, OK. Pittsburgh, PA. Sioux Falls, SD.
Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors
Conditions: Mesothelioma, Locally Advanced Solid Tumor
Last Updated: August 22, 2022
Status: Recruiting
Locations: Boston, Massachusetts. Boston, Massachusetts. Nashville, Tennessee. Houston, Texas. San Antonio, Texas. Fairfax, Virginia.
APG-2449 in Patients With Advanced Solid Tumors
Conditions: Mesothelioma, Mesothelioma, Malignant
Last Updated: August 19, 2022
Status: Recruiting
A Beta-only IL-2 ImmunoTherapY (ABILITY) Study
Conditions: Mesothelioma
Last Updated: August 17, 2022
Status: Recruiting
Locations: Boca Raton, Florida. Orlando, Florida. Atlanta, Georgia.
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
Conditions: Endometrial Neoplasms, Mesothelioma, Diffuse Intrinsic Pontine Glioma
Last Updated: August 15, 2022
Status: Recruiting
Locations: Houston, Texas.
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Conditions: Adenocarcinoma, Sarcoma, Mesothelioma, Mesothelioma, Malignant, Sarcoma, Ewing, Chondrosarcoma
Last Updated: August 12, 2022
Status: Recruiting
Locations: Scottsdale, AZ. Duarte, CA. Los Angeles, CA. Santa Monica, CA. Aurora, CO. Atlanta, GA. Chicago, IL. Ann Arbor, MI. Grand Rapids, MI. New York, NY. Cleveland, OH. Philadelphia, PA. Houston, TX. San Antonio, TX.
KZR-261 in Subjects With Advanced Solid Malignancies
Conditions: Mesothelioma, Neoplasms
Last Updated: August 12, 2022
Status: Recruiting
Locations: Los Angeles, California. Tampa, Florida. Atlanta, Georgia. Philadelphia, Pennsylvania. Nashville, Tennessee. San Antonio, Texas. Fairfax, Virginia.
Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Conditions: Mesothelioma, Non-Small Cell Lung Cancer, Pancreatic Adenocarcinoma, Solid Tumor
Last Updated: August 10, 2022
Status: Recruiting
Locations: Denver, Colorado. Boston, Massachusetts. New York, New York. Nashville, Tennessee. Houston, Texas. San Antonio, Texas.
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Conditions: Mesothelioma
Last Updated: August 5, 2022
Status: Recruiting
Locations: Duarte, California. La Jolla, California. Aurora, Colorado. Denver, Colorado. Boston, Massachusetts. Philadelphia, Pennsylvania. San Antonio, Texas.
A Study of NX-1607 in Adults With Advanced Malignancies
Conditions: Carcinoma, Neoplasms, Triple Negative Breast Neoplasms, Mesothelioma, Mesothelioma, Malignant, Mesothelioma, Malignant Pleural, Squamous Cell Carcinoma of Head and Neck, Non-Small Cell Lung Cancer, Carcinoma, Ovarian Epithelial
Last Updated: July 27, 2022
Status: Recruiting
Phase II Trial of Radical Pleurectomy With or Without Intraoperative PDT for Malignant Pleural Mesothelioma
Conditions: Mesothelioma, Mesothelioma, Malignant
Last Updated: July 26, 2022
Status: Recruiting
Locations: Buffalo, NY. Philadelphia, PA.
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
Conditions: Carcinoma, Merkel Cell, Mesothelioma, Neuroendocrine Tumors, Neoplasms, Squamous Cell, Carcinoma, Squamous Cell, Microsatellite Instability
Last Updated: July 22, 2022
Status: Recruiting
Locations: Pittsburgh, PA.
Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma
Conditions: Mesothelioma, Mesothelioma, Malignant
Last Updated: July 22, 2022
Status: Recruiting
Locations: Baltimore, MD. Baltimore, MD. Houston, TX.
Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion
Conditions: Neoplasms
Last Updated: July 22, 2022
Status: Recruiting
Locations: Scottsdale, Arizona. Duarte, California. Indianapolis, Indiana. Baltimore, Maryland. Boston, Massachusetts. New York, New York. New York, New York. Oklahoma City, Oklahoma. Nashville, Tennessee. Houston, Texas. San Antonio, Texas.
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
Conditions: Carcinoma, Melanoma, Carcinoma, Renal Cell, Mesothelioma, Cholangiocarcinoma, Meningioma, Disease Susceptibility
Last Updated: July 11, 2022
Status: Recruiting
Locations: Columbus, Ohio.
Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies
Conditions: Neoplasms, Neoplasm Metastasis
Last Updated: July 11, 2022
Status: Recruiting
Locations: Grand Rapids, Michigan. Houston, Texas. San Antonio, Texas.
Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery
Conditions: Carcinoma, Non-Small-Cell Lung, Mesothelioma, Mesothelioma, Malignant, Lung Neoplasms, Pleural Diseases
Last Updated: June 21, 2022
Status: Recruiting
Locations: Buffalo, NY.
A Study of Pembrolizumab and Cryoablation in People With Mesothelioma
Conditions: Mesothelioma
Last Updated: June 16, 2022
Status: Recruiting
Locations: Basking Ridge, New Jersey. Middletown, New Jersey. Montvale, New Jersey. Commack, New York. Harrison, New York. New York, New York. Uniondale, New York.
Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors
Conditions: Mesothelioma
Last Updated: June 7, 2022
Status: Recruiting
Locations: Boston, Massachusetts. Grand Rapids, Michigan. Philadelphia, Pennsylvania. Nashville, Tennessee. Houston, Texas. San Antonio, Texas.
Study of the Efficacy and Safety of the Bintrafusp Alfa in Previously Treated Advanced Malignant Pleural Mesothelioma
Conditions: Mesothelioma, Mesothelioma, Malignant
Last Updated: June 2, 2022
Status: Recruiting
Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
Conditions: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Mesothelioma, Malignant, Cholangiocarcinoma
Last Updated: May 27, 2022
Status: Recruiting
Locations: San Francisco, CA. Bethesda, MD. New York, NY. Philadelphia, PA. Nashville, TN. Houston, TX.
A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
Conditions: Neoplasm Metastasis, Melanoma, Primary Myelofibrosis
Last Updated: May 20, 2022
Status: Recruiting
Surgery for Mesothelioma After Radiation Therapy Using Exquisite Systemic Therapy
Conditions: Mesothelioma
Last Updated: May 19, 2022
Status: Recruiting
Locations: Toronto, California.
Magnetic Resonance Imaging for Detection of Peritoneal Mesothelioma
Conditions: Mesothelioma, Mesothelioma, Malignant
Last Updated: May 18, 2022
Status: Recruiting
Locations: Chicago, IL.
Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for the Treatment of Resectable, Refractory, or Recurrent Abdominal or Pelvic Tumors in Pediatric Patients, T.O.A.S.T. I.T. Study
Conditions: Carcinoma, Neoplasms, Sarcoma, Mesothelioma
Last Updated: May 11, 2022
Status: Recruiting
Locations: Rochester, MN.
Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)
Conditions: Mesothelioma
Last Updated: May 3, 2022
Status: Recruiting
Nivolumab With Chemotherapy in Pleural Mesothelioma After Surgery
Conditions: Mesothelioma, Mesothelioma, Malignant
Last Updated: April 15, 2022
Status: Recruiting
Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma
Conditions: Mesothelioma, Mesothelioma, Malignant
Last Updated: April 7, 2022
Status: Recruiting
Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma
Conditions: Mesothelioma, Mesothelioma, Malignant
Last Updated: April 4, 2022
Status: Recruiting
Locations: New York, New York.
Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers
Conditions: Mesothelioma, Mesothelioma, Malignant
Last Updated: March 23, 2022
Status: Recruiting
Locations: Boston, MA.
CAR T Cells in Mesothelin Expressing Cancers
Conditions: Mesothelioma, Mesothelioma, Malignant, Fallopian Tube Neoplasms, Adenocarcinoma of Lung
Last Updated: March 10, 2022
Status: Recruiting
Locations: Philadelphia, PA.
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
Conditions: Carcinoma, Merkel Cell, Lymphoma, Carcinoma, Endometrial Neoplasms, Mesothelioma, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Small Cell
Last Updated: March 4, 2022
Status: Recruiting
A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma
Conditions: Mesothelioma
Last Updated: March 2, 2022
Status: Recruiting
Locations: Chicago, Illinois.
Glypican-1 Expression in Epithelioid Mesothelioma, Adenocarcinoma and SCC of the Lung
Conditions: Lung Cancer Adenocarcinoma, Lung Cancer Squamous Cell|, Mesothelioma
Last Updated: February 8, 2022
Status: Recruiting
Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity
Conditions: Carcinoma, Carcinoma, Renal Cell, Endometrial Neoplasms, Mesothelioma, Carcinoma, Non-Small-Cell Lung
Last Updated: January 31, 2022
Status: Recruiting
A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma
Conditions: Mesothelioma, Mesothelioma, Malignant
Last Updated: January 28, 2022
Status: Recruiting
Locations: Basking Ridge, NJ. Middletown, NJ. Montvale, NJ. Commack, NY. Harrison, NY. New York, NY. Uniondale, NY.
eRAPID: Online Symptom Reporting in Lung Cancer
Conditions: Lung Neoplasms, Small Cell Lung Carcinoma, Mesothelioma
Last Updated: January 27, 2022
Status: Recruiting
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma
Conditions: Lung Neoplasms, Mesothelioma, Mesothelioma, Malignant
Last Updated: January 26, 2022
Status: Recruiting
Locations: Cleveland, OH. Philadelphia, PA. Nashville, TN.
Impact of Cardiac Coherence on Anxiety in Patients Operated on for a Peritoneal Carcinosis
Conditions: Mesothelioma, Carcinoma, Peritoneal Neoplasms, Pseudomyxoma Peritonei
Last Updated: January 24, 2022
Status: Recruiting
Assessment of Histologic Prognostic Factors in Peritoneal Malignant Mesothelioma
Conditions: Malignant Peritoneal Mesothelioma
Last Updated: January 14, 2022
Status: Recruiting
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
Conditions: Mesothelioma, Mesothelioma, Malignant, Lung Neoplasms
Last Updated: January 5, 2022
Status: Recruiting
Locations: Houston, TX.
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
Conditions: Advanced Solid Tumors, Glioblastoma, Soft Tissue Sarcoma, SCLC, Mesothelioma, Neuroendocrine Tumors, Colorectal Neoplasms, Endometrial Carcinoma, Carcinoma, Ovarian Epithelial, Pancreatic Adenocarcinoma
Last Updated: December 2, 2021
Status: Recruiting
Locations: Boston, MA. Boston, MA.
A Two-part Study to Characterize Drug-Drug Interaction Effects on Steady-State Pharmacokinetics of Oral Tazemetostat
Conditions: Lymphoma, Neoplasms, Sarcoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Mesothelioma, Hematologic Neoplasms, Rhabdoid Tumor, Sarcoma, Synovial, Carcinoma, Medullary
Last Updated: December 15, 2021
Status: Recruiting
Locations: Encinitas, CA. Los Angeles, CA. Chicago, IL. Grand Rapids, MI. Canton, OH. Cincinnati, OH. Dallas, TX.
Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma
Conditions: Mesothelioma, Mesothelioma, Malignant
Last Updated: December 9, 2021
Status: Recruiting
Locations: Tampa, FL. Boston, MA. Rochester, MN. Basking Ridge, NJ. Middletown, NJ. Montvale, NJ. Commack, NY. Harrison, NY. New York, NY. Rockville Centre, NY. Sleepy Hollow, NY. Uniondale, NY. Houston, TX.
Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma
Conditions: Mesothelioma, Mesothelioma, Malignant, Wilms Tumor
Last Updated: December 8, 2021
Status: Recruiting
Locations: Basking Ridge, NJ. Middletown, NJ. Commack, NY. Harrison, NY. New York, NY. Uniondale, NY.
Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma
Conditions: Mesothelioma, Mesothelioma, Malignant
Last Updated: December 2, 2021
Status: Recruiting
Locations: Birmingham, AL. Phoenix, AZ. Scottsdale, AZ. Duarte, CA. La Jolla, CA. Los Angeles, CA. Los Angeles, CA. Newport Beach, CA. Aurora, CO. Aventura, FL. Coral Gables, FL. Deerfield Beach, FL. Jacksonville, FL. Miami, FL. Miami, FL. Plantation, FL. Chicago, IL. Chicago, IL. Lexington, KY. Baltimore, MD. Baltimore, MD. Boston, MA. Boston, MA. Rochester, MN. Creve Coeur, MO. Saint Louis, MO. Saint Louis, MO. Saint Peters, MO. Durham, NC. Pittsburgh, PA. Dallas, TX. Salt Lake City, UT.
Stereotactic Body Radiation Therapy With Immunotherapy for the Treatment of Mesothelioma
Conditions: Mesothelioma, Mesothelioma, Malignant
Last Updated: December 2, 2021
Status: Recruiting
Locations: Rochester, MN.
Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma
Conditions: Mesothelioma, Mesothelioma, Malignant
Last Updated: November 6, 2021
Status: Recruiting
Locations: Boston, MA. Rochester, MN.
Treatment of Malignant Peritoneal Mesothelioma (MESOTIP)
Conditions: Mesothelioma, Mesothelioma, Malignant, Carcinoma, Peritoneal Neoplasms
Last Updated: November 4, 2021
Status: Recruiting
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors Enriched for Tumors With NF2 Gene Mutations
Conditions: Mesothelioma
Last Updated: November 2, 2021
Status: Recruiting
Locations: Chicago, Illinois. Boston, Massachusetts. Boston, Massachusetts. Houston, Texas. San Antonio, Texas.
Register With Patients in Which Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) Was Performed
Conditions: Mesothelioma, Carcinoma, Peritoneal Neoplasms, Pseudomyxoma Peritonei, Hyperthermia, Fever
Last Updated: October 15, 2021
Status: Recruiting
UNITO-001-A Phase II Study in HRR/PDL1 Positive MPM/NSCLC
Conditions: Mesothelioma
Last Updated: October 14, 2021
Status: Recruiting
A Feasibility Study Evaluating Surgery for Mesothelioma After Radiation Therapy Using Extensive Pleural Resection
Conditions: Mesothelioma, Mesothelioma, Malignant
Last Updated: October 4, 2021
Status: Recruiting
Short Neoadjuvant Hemithoracic IMRT for MPM
Conditions: Mesothelioma, Mesothelioma, Malignant
Last Updated: October 4, 2021
Status: Recruiting
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors
Conditions: Carcinoma, Breast Neoplasms, Carcinoma, Squamous Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms, Mesothelioma, Squamous Cell Carcinoma of Head and Neck
Last Updated: October 3, 2021
Status: Recruiting
PIPAC With Nab-paclitaxel and Cisplatin in Peritoneal Carcinomatosis
Conditions: Carcinoma, Peritoneal Neoplasms
Last Updated: September 21, 2021
Status: Recruiting
Dose Individualization of Pemetrexed - IMPROVE-II
Conditions: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Mesothelioma, Malignant
Last Updated: September 14, 2021
Status: Recruiting
Dose Individualization of Pemetrexed - IMPROVE-III
Conditions: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Mesothelioma, Malignant
Last Updated: September 14, 2021
Status: Recruiting
Feasibility of the LUM Imaging System for Peritoneal Surface Malignancies
Conditions: Neoplasms, Peritoneal Neoplasms
Last Updated: September 13, 2021
Status: Recruiting
Locations: Boston, MA.
Real World Study of MPM in China
Conditions: Mesothelioma, Mesothelioma, Malignant Pleural
Last Updated: September 13, 2021
Status: Recruiting
Feasibility of the LUM Imaging System for Peritoneal Surface Malignancies
Conditions: None
Last Updated: September 13, 2021
Status: Recruiting
Locations: Boston, MA.
A Pilot Study to Explore the Role of Gut Flora in Metastatic Mesothelioma
Conditions: Mesothelioma, Mesothelioma, Malignant
Last Updated: September 5, 2021
Status: Recruiting
Locations: Ventura, CA.
Cardiac MRI Biomarker Testing (GCC 1618)
Conditions: Mesothelioma, Thymus Neoplasms
Last Updated: August 16, 2021
Status: Recruiting
Efficacy of Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors
Conditions: Carcinoma, Breast Neoplasms, Melanoma, Carcinoma, Squamous Cell, Adenocarcinoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms, Mesothelioma, Cholangiocarcinoma, Squamous Cell Carcinoma of Head and Neck, Endometrial Neoplasms, Adenocarcinoma of Lung, Thyroid Neoplasms, Esophageal Neoplasms, Cystadenocarcinoma, Carcinosarcoma, Urinary Bladder Neoplasms, Adenomyoepithelioma, Adenocarcinoma, Clear Cell, Cystadenocarcinoma, Serous
Last Updated: August 13, 2021
Status: Recruiting
Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)
Conditions: Mesothelioma, Mesothelioma, Malignant
Last Updated: August 9, 2021
Status: Recruiting
Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors
Conditions: Uterine Cervical Neoplasms, Mesothelioma, Carcinoma, Non-Small-Cell Lung, Thymoma, Thymus Neoplasms
Last Updated: July 31, 2021
Status: Recruiting
SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II
Conditions: Carcinoma, Non-Small-Cell Lung, Mesothelioma, Mesothelioma, Malignant
Last Updated: July 23, 2021
Status: Recruiting
Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma
Conditions: Mesothelioma, Mesothelioma, Malignant
Last Updated: July 21, 2021
Status: Recruiting
Locations: Tampa, FL. Baltimore, MD. Detroit, MI. Minneapolis, MN.
Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies
Conditions: Pseudomyxoma Peritonei, Colorectal Carcinoma, Mesothelioma, Ovarian Carcinoma, Peritoneal Neoplasms
Last Updated: July 21, 2021
Status: Recruiting
Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma
Conditions: Mesothelioma, Mesothelioma, Malignant
Last Updated: July 19, 2021
Status: Recruiting
A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma
Conditions: Mesothelioma, Mesothelioma, Malignant
Last Updated: June 30, 2021
Status: Recruiting
Locations: Chicago, IL.
The IMmunotherapy Pleural 5-ALA PDT
Conditions: Mesothelioma, Mesothelioma, Malignant
Last Updated: May 18, 2021
Status: Recruiting
Olaparib in Patients With HRD Malignant Mesothelioma
Conditions: Mesothelioma, Mesothelioma, Malignant
Last Updated: May 12, 2021
Status: Recruiting
Locations: Chicago, IL.
Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Surgery or Biopsy
Conditions: Stomach Neoplasms, Esophageal Neoplasms, Mesothelioma, Gastrointestinal Stromal Tumors, Anus Neoplasms, Pancreatic Neoplasms, Liver Neoplasms, Carcinoma, Hepatocellular, Gastrointestinal Neoplasms
Last Updated: May 12, 2021
Status: Recruiting
BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma
Conditions: Mesothelioma, Mesothelioma, Malignant
Last Updated: April 30, 2021
Status: Recruiting
Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours
Conditions: Mesothelioma, Mesothelioma, Malignant
Last Updated: April 30, 2021
Status: Recruiting
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
Conditions: Carcinoma, Melanoma, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Mesothelioma, Mesothelioma, Malignant, Nasopharyngeal Carcinoma, Cholangiocarcinoma, Breast Neoplasms, Lung Neoplasms, Carcinoma, Basal Cell, Squamous Cell Carcinoma of Head and Neck, Colorectal Neoplasms, Endometrial Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Neuroendocrine, Thymoma, Small Cell Lung Carcinoma, Anus Neoplasms, Vulvar Neoplasms
Last Updated: April 28, 2021
Status: Recruiting
Locations: Los Angeles, CA. Los Angeles, CA. San Diego, CA. San Francisco, CA. Atlanta, GA. Chicago, IL. Fairway, KS. Detroit, MI. New York, NY. New York, NY. Portland, OR. Philadelphia, PA. Pittsburgh, PA. Houston, TX. Salt Lake City, UT. Charlottesville, VA. Seattle, WA.
Study of SO-C101 and SO-C101 in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors
Conditions: Carcinoma, Merkel Cell, Carcinoma, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Carcinoma, Squamous Cell, Ovarian Neoplasms, Carcinoma, Hepatocellular, Stomach Neoplasms, Uterine Cervical Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms, Mesothelioma, Mesothelioma, Malignant, Squamous Cell Carcinoma of Head and Neck, Biliary Tract Neoplasms, Anus Neoplasms, Thymus Neoplasms, Microsatellite Instability
Last Updated: April 15, 2021
Status: Recruiting
Locations: New Haven, CT. Houston, TX.
Pembrolizumab and Hypofractionated Stereotactic Radiotherapy in Patients With Malignant Pleural Mesothelioma
Conditions: Mesothelioma, Mesothelioma, Malignant
Last Updated: April 12, 2021
Status: Recruiting
Oral TrkA Inhibitor VMD-928 for Treatment of Advanced Adult Solid Tumors or Lymphoma
Conditions: Lymphoma, Carcinoma, Prostatic Neoplasms, Leukemia, Myeloid, Melanoma, Carcinoma, Squamous Cell, Leukemia, Myeloid, Acute, Ovarian Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Non-Hodgkin, Stomach Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Mesothelioma, Mesothelioma, Malignant, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Adenoid Cystic, Thymoma, Lung Neoplasms
Last Updated: March 11, 2021
Status: Recruiting
Locations: Duarte, CA. Morristown, NJ. New York, NY. Houston, TX. Milwaukee, WI.
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
Conditions: Neoplasm Metastasis, Brain Neoplasms, Astrocytoma, Mesothelioma, Cholangiocarcinoma, Esophageal Neoplasms, Tongue Neoplasms, Thymoma, Urologic Neoplasms
Last Updated: March 8, 2021
Status: Recruiting
Pleurectomy/ Decortication (P/D) Preceded or Followed by Chemotherapy in Patients With Early Stage MPM
Conditions: Mesothelioma, Mesothelioma, Malignant
Last Updated: March 5, 2021
Status: Recruiting
Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients
Conditions: Mesothelioma, Mesothelioma, Malignant
Last Updated: March 2, 2021
Status: Recruiting
Accelerated Hypofractionated Radiotherapy in the Treatment of Malignant Pleural Mesothelioma
Conditions: Mesothelioma, Mesothelioma, Malignant
Last Updated: February 26, 2021
Status: Recruiting
Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients With PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies
Conditions: Mesothelioma, Mesothelioma, Malignant, Disease Progression
Last Updated: February 26, 2021
Status: Recruiting
Evaluation of the Clinical/Biological Characteristics, Efficacy and Safety of Patients With Malignant Pleural Mesothelioma, Treated by Immunotherapy
Conditions: Mesothelioma, Mesothelioma, Malignant
Last Updated: February 25, 2021
Status: Recruiting
DENdritic Cell Immunotherapy for Mesothelioma
Conditions: Mesothelioma, Mesothelioma, Malignant
Last Updated: January 27, 2021
Status: Recruiting
Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma
Conditions: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Mesothelioma, Malignant
Last Updated: January 22, 2021
Status: Recruiting
Autologous Dendritic Cell Vaccination in Mesothelioma
Conditions: Mesothelioma, Mesothelioma, Malignant
Last Updated: January 19, 2021
Status: Recruiting
Rehabilitation by Effort for Patients With Advanced Bronchial Cancer
Conditions: Mesothelioma, Mesothelioma, Malignant, Carcinoma, Bronchogenic
Last Updated: July 29, 2020
Status: Recruiting
αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors
Conditions: Mesothelioma
Last Updated: July 28, 2020
Status: Recruiting
Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma
Conditions: Mesothelioma, Mesothelioma, Malignant, Hyperthermia
Last Updated: July 14, 2020
Status: Recruiting
HMPL-453 in Advanced Malignant Mesothelioma
Conditions: Mesothelioma, Mesothelioma, Malignant, Lung Neoplasms
Last Updated: June 16, 2020
Status: Recruiting
177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours
Conditions: Mesothelioma, Neuroendocrine Tumors, Thymoma
Last Updated: May 5, 2020
Status: Recruiting
Association Between Proton Pump Inhibitors and Hematologic Toxicity of Pemetrexed
Conditions: Mesothelioma
Last Updated: December 13, 2019
Status: Recruiting
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
Conditions: Leukemia, Multiple Myeloma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Mesothelioma, Sarcoma, Synovial, Esophageal Neoplasms, Carcinoma, Renal Cell, Kidney Neoplasms
Last Updated: December 11, 2019
Status: Recruiting
Mesothelioma and Radical Surgery 2
Conditions: Mesothelioma, Mesothelioma, Malignant
Last Updated: October 28, 2019
Status: Recruiting
International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)
Conditions: Mesothelioma, Pancreatic Neoplasms, Gallbladder Neoplasms, Pseudomyxoma Peritonei, Appendiceal Neoplasms, Pleural Effusion, Ascites
Last Updated: October 7, 2019
Status: Recruiting
uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung
Conditions: Carcinoma, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Mesothelioma, Malignant, Carcinoma, Neuroendocrine
Last Updated: November 21, 2016
Status: Recruiting
